Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations

被引：0
|
作者：
Nizamuddin, Imran
Doukas, Peter
de Viveiros, Pedro Antonio Hermida
Mi, Xinlei
Katam, Neelima
Chae, Young Kwang
Behdad, Amir
Wehbe, Firas Hazem
Mahalingam, Devalingam
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Northwestern Univ, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2634
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA
    Barnett, Reagan
    Lanka, Sree M.
    Clemens, Keelia M.
    Kiedrowski, Lesli Ann
    Babiker, Hani M.
    Bryce, Alan Haruo
    Meyer, Haley M.
    Choi, Yujin
    Garje, Rohan
    Gao, Xin
    Chang, Richard Y.
    Jang, Albert
    Gulhati, Pat
    Bilen, Mehmet Asim
    Barata, Pedro C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Analysis of association between homologous recombination deficiency and tumor mutational burden in solid tumors
    Li, Hua
    Wu, Liqun
    Shou, Tao
    Jiang, Bo
    Zhuang, Li
    Li, Kunsong
    Tan, Xiang
    Guo, Chao
    Guo, Weidong
    Guan, Yan
    Chen, Zheng
    Ding, Xiao
    Guo, Jun
    Du, Zhenfang
    Cui, Qiang
    Che, Yue
    Yao, Ming
    CANCER RESEARCH, 2018, 78 (13)
  • [23] The Impact of Tumor Volume Burden Reduction for Pediatric Solid Tumors by Immune Checkpoint Inhibitors
    Saito, Takeshi
    Fuchimoto, Yasushi
    Fukui, Keisuke
    Shimizu, Takahiro
    Kuroda, Tatsuo
    Hirabayashi, Takeshi
    Hakamada, Kenichi
    PEDIATRIC BLOOD & CANCER, 2020, 67
  • [24] The association of mismatch repair gene alterations with elevated tumor mutational burden in microsatellite stable gastrointestinal cancers
    O'Donnell, Conor D.
    Zhu, Mojun
    Xie, Hao
    CANCER RESEARCH, 2024, 84 (06)
  • [25] Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)
    Schrock, A. B.
    Fabrizio, D.
    He, Y.
    Chung, J.
    Resnick, M.
    Stephens, P. J.
    Ross, J. S.
    Miller, V. A.
    Ramkissoon, S.
    Elvin, J. A.
    Ali, S. M.
    Fakih, M.
    Klempner, S. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] The inflammatory tumor microenvironment in patients with solid tumors with brain metastases after progression to immune checkpoint inhibitor therapy
    Starzer, A. M.
    Kleinberger, M.
    Feldmann, K.
    Tomasich, E.
    Hatziioannou, T.
    Paiato, C.
    Heller, G.
    Kreminger, J.
    Traint, S.
    Steindl, A.
    Ressler, J. M.
    Widhalm, G.
    Gatterbauer, B.
    Dieckmann, K.
    Muellauer, L.
    Preusser, M.
    Berghoff, A. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 272 - 272
  • [27] Prevalence of mature tertiary lymphoid structures and association with tumor mutational burden in patients with solid tumors
    Brunet, Maxime
    Vanhersecke, Lucile
    Le Loarer, Francois
    Soubeyran, Isabelle
    Soubeyran, Isabelle
    Italiano, Antoine
    CANCER RESEARCH, 2023, 83 (07)
  • [28] Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types
    Sinha, Neelam
    Sinha, Sanju
    Valero, Christina
    Schaffer, Alejandro A.
    Aldape, Kenneth
    Litchfield, Kevin
    Chan, Timothy A.
    Morris, Luc G. T.
    Ruppin, Eytan
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
  • [29] Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
    Sinha, Neelam
    Sinha, Sanju
    Valero, Cristina
    Scha, Alejandro A.
    Aldape, Kenneth
    Litch, Kevin
    Chan, Timothy A.
    Morris, Luc G. T.
    Ruppin, Eytan
    CANCER RESEARCH, 2022, 82 (11) : 2076 - 2083
  • [30] FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
    Marcus, Leigh
    Fashoyin-Aje, Lola A.
    Donoghue, Martha
    Yuan, Mengdie
    Rodriguez, Lisa
    Gallagher, Pamela S.
    Philip, Reena
    Ghosh, Soma
    Theoret, Marc R.
    Beaver, Julia A.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4685 - 4689
12345